Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Trials

Value of novel agents and intensive therapy for patients with multiple myeloma

Bone Marrow Transplantation volume 49, pages 422–425 (2014)Cite this article

Subjects

Abstract

We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide- or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first year. Survival times were calculated after a landmark of 1 year from start of therapy, so that subsequent median survival was 8.9 years for patients with CR, 4.9 years for those with PR and 0.6 year for patients with NR (P<0.001). Multivariate analyses confirmed CR or PR as the major favorable factors with less impact on prognosis for age or disease stage. Both novel agents and high-dose therapy (HDT) resulted in high frequencies of PR or CR, with early HDT useful for many patients with NR or PR in improving response status and subsequent survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  2. Child J, Morgan G, Davies F, Owen R, Bell S, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Eng J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  3. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R . Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.

    Article  CAS  Google Scholar 

  4. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323.

    Article  CAS  Google Scholar 

  5. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27: 3518–3525.

    Article  CAS  Google Scholar 

  6. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783.

    Article  CAS  Google Scholar 

  7. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R . Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235–239.

    Article  CAS  Google Scholar 

  8. Wang M, Delasalle K, Giralt S, Alexanian R . Rapid control of previously untreated multiple myeloma with bortezomib—lenalidomide—dexamethasone. Hematology 2010; 15: 70–73.

    Article  CAS  Google Scholar 

  9. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 2009; 45: 498–504.

    Article  Google Scholar 

  10. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    Article  Google Scholar 

  11. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043.

    Article  CAS  Google Scholar 

  12. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S . Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229–234.

    Article  CAS  Google Scholar 

  13. Durie B, Harousseau JL, Miguel J, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  Google Scholar 

  14. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  Google Scholar 

  15. Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  16. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Rep 1966; 50: 163–170.

    CAS  Google Scholar 

  17. Anderson J, Cain K, Gelber R . Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710–719.

    Article  CAS  Google Scholar 

  18. Cox D . Regression models and life tables. J Royal Stat Soc 1972; 34: 187–220.

    Google Scholar 

  19. Lahuerta J, Mateos M, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775–5782.

    Article  Google Scholar 

  20. Gertz M, Kumar S, Lacy M, Dispenzeri A, Dingli D, Hayman S et al. Stem cell transplantation in multiple myeloma; impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348–2353.

    Article  CAS  Google Scholar 

  21. Snapper I, Kahn A . Multiple Myeloma. Semin Hematol 1964; 124: 87–143.

    Google Scholar 

  22. Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained for 3 years from treatment initiation is a powerful surrogate marker for extended survival in multiple myeloma. Cancer 2008; 113: 355–359.

    Article  Google Scholar 

  23. Kumar S, Dingli S, Dispenzeri A, Lacy M, Hayman S, Buadi F et al. Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant 2008; 42: 259–264.

    Article  Google Scholar 

Download references

Acknowledgements

We are indebted to Lisa Foucheaux-Heider for typing this paper.

Author information

Authors and Affiliations

  1. University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

    R Alexanian, M Wang, K Delasalle, S Wang, M Qazilbash, B Handy & D Weber

Authors
  1. R Alexanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Delasalle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Qazilbash
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Handy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Delasalle.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alexanian, R., Wang, M., Delasalle, K. et al. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant 49, 422–425 (2014). https://doi.org/10.1038/bmt.2013.189

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.189

Keywords

Search

Advanced search

Quick links